- Home
- STXS vs SLS Comparison
STXS vs SLS Comparison
Compare STXS & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STXS
- SLS
- Stock Information
- Founded
- STXS 1990
- SLS 2012
- Country
- STXS United States
- SLS United States
- Employees
- STXS N/A
- SLS N/A
- Industry
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- STXS Health Care
- SLS Health Care
- Exchange
- STXS Nasdaq
- SLS Nasdaq
- Market Cap
- STXS 151.3M
- SLS 169.6M
- IPO Year
- STXS 2004
- SLS N/A
- Fundamental
- Price
- STXS $2.13
- SLS $1.54
- Analyst Decision
- STXS
- SLS
- Analyst Count
- STXS 0
- SLS 0
- Target Price
- STXS N/A
- SLS N/A
- AVG Volume (30 Days)
- STXS 207.9K
- SLS 2.5M
- Earning Date
- STXS 08-11-2025
- SLS 08-12-2025
- Dividend Yield
- STXS N/A
- SLS N/A
- EPS Growth
- STXS N/A
- SLS N/A
- EPS
- STXS N/A
- SLS N/A
- Revenue
- STXS $27,510,000.00
- SLS N/A
- Revenue This Year
- STXS $25.90
- SLS N/A
- Revenue Next Year
- STXS $60.57
- SLS N/A
- P/E Ratio
- STXS N/A
- SLS N/A
- Revenue Growth
- STXS 1.50
- SLS N/A
- 52 Week Low
- STXS $1.54
- SLS $0.77
- 52 Week High
- STXS $2.72
- SLS $2.12
- Technical
- Relative Strength Index (RSI)
- STXS 47.58
- SLS 45.96
- Support Level
- STXS $2.06
- SLS $1.47
- Resistance Level
- STXS $2.36
- SLS $1.73
- Average True Range (ATR)
- STXS 0.11
- SLS 0.11
- MACD
- STXS -0.01
- SLS -0.02
- Stochastic Oscillator
- STXS 19.70
- SLS 19.44
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.